CanSinoBIO (SSE: 688185, HKEX: 06185) commits to research, production and commercialization of innovative vaccines. It possesses five integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination, formulation and mRNA www.cansinotech.com
Products, services, technology
As of today, it has established a robust pipeline of 17 vaccines preventing 12 diseases, including the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) and the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197).
- Pierre MORGON
